

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(12)

Oversættelse af europæisk patentskrift

(10) **DK/EP 3729441 T3**

-
- (51) Int.Cl.: **G 16 B 20/20 (2019.01)** **C 12 Q 1/6827 (2018.01)** **G 16 B 30/10 (2019.01)**
G 16 B 40/00 (2019.01)
- (45) Oversættelsen bekendtgjort den: **2024-06-17**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2024-03-13**
- (86) Europæisk ansøgning nr.: **18840007.1**
- (86) Europæisk indleveringsdag: **2018-12-29**
- (87) Den europæiske ansøgnings publiceringsdag: **2020-10-28**
- (86) International ansøgning nr.: **US2018068066**
- (87) Internationalt publikationsnr.: **WO2019133937**
- (30) Prioritet: **2017-12-29 US 201762612048 P** **2018-07-17 US 201862699685 P**
2018-12-28 US 201816235901
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Grail, LLC, 1525 O'Brien Drive, Menlo Park, CA 94025, USA**
- (72) Opfinder: **HUBBELL, Earl, Grail, Inc. 1525 O'brien Drive, Menlo Park, CA 94025, USA**
- (74) Fuldmægtig i Danmark: **Patrade A/S, Ceresbyen 75, 6., 8000 Århus C, Danmark**
- (54) Benævnelse: **PÅVISNING AF MIKROSATELLIT INSTABILITET**
- (56) Fremdragne publikationer:
US-A1- 2014 235 456
GYMREK M ET AL: "IobSTR: A short tandem repeat profiler for personal genomes", GENOME RESEARCH, vol. 22, no. 6, 20 April 2012 (2012-04-20) , pages 1154-1162, XP055560142, US ISSN: 1088-9051, DOI: 10.1101/gr.135780.111
HAUSE R J ET AL: "Classification and characterization of microsatellite instability across 18 cancer types", NATURE MEDICINE, vol. 22, no. 11, 3 October 2016 (2016-10-03), pages 1342-1350, XP055494424, New York ISSN: 1078-8956, DOI: 10.1038/nm.4191
BUTLAND S L ET AL: "CAG-encoded polyglutamine length polymorphism in the human genome", BMC GENOMICS, BIOMED CENTRAL, vol. 8, no. 1, 22 May 2007 (2007-05-22), page 126, XP021027940, ISSN: 1471-2164, DOI: 10.1186/1471-2164-8-126
MISSIRLIS P I ET AL: "Satellog: A database for the identification and prioritization of satellite repeats in disease association studies", BMC BIOINFORMATICS, BIOMED CENTRAL, LONDON, GB, vol. 6, no. 1, 10 June 2005 (2005-06-10), page 145, XP021000738, ISSN: 1471-2105, DOI: 10.1186/1471-2105-6-145
GYMREK M: "A genomic view of short tandem repeats", CURRENT OPINION IN GENETICS & DEVELOPMENT, vol. 44, 16 February 2017 (2017-02-16), pages 9-16, XP085047725, ISSN: 0959-437X, DOI: 10.1016/J.GDE.2017.01.012

Fortsættes ...

DESCRIPTION

Description

BACKGROUND

1. FIELD OF ART

[0001] This disclosure generally relates to targeted sequencing and more specifically to using both cell free DNA and genomic DNA detecting microsatellite instability.

2. DESCRIPTION OF THE RELATED ART

[0002] Computational techniques can be used on DNA sequencing data to identify mutations or variants in DNA that may correspond to various types of cancer or other diseases. Further, detecting microsatellite instability (MSI) in those cancers can be informative for method of treatment, likelihood of cure, severity of cancer, progression of cancer, etc. Cancer and MSI diagnosis or prediction may be performed by analyzing a biological sample such as a tissue biopsy or blood drawn from a subject. Methods of detecting MSI in tissue based tumor DNA are known in the art. However, detecting MSI in tumor DNA that originated from circulating cell free DNA (cfDNA) is challenging because circulating tumor DNA (ctDNA) is present at low levels relative to other molecules in cfDNA. Currently, existing methods to identify MSI in tissue based tumor DNA are unreliable in detecting MSI in samples including cfDNA.

[0003] US20140235456A1 discloses a method of identifying an increased risk of developing cancer based on an alteration in the microsatellite profile of the subject. However, this prior art does not disclose calculating, for each marker, a marker significance indicating the significance and viability for the marker in detecting MSI.

SUMMARY

[0004] Early detection of cancer in subjects is important as it allows cancer patients (i.e., subjects) a greater chance of surviving the disease. For some cancers, microsatellite instability (MSI) in cell-free DNA can indicate the presence of a cancer which would, otherwise, be hard to detect. As such, subjects can generate a DNA sample for analysis (e.g., a blood sample) to determine a likelihood that MSI exists and, thereby, determine a likelihood that the sample

includes cancer.

[0005] The present invention concerns a method (400) of detecting a likelihood of cancer in an individual based on MSI, and a corresponding system, as defined in the appended claims.

[0006] A processing system is configured to process the sample by separating cfDNA and/or ctDNA, and gDNA (e.g., wbcDNA) from the sample for generating sequence reads that may include MSI. The processing system generates candidate variants from the sequence reads for the cfDNA and/or ctDNA (i.e., variants) and the gDNA (i.e., normals). The processing system compares the variant (i.e., test reads) to the normals (i.e., control reads) to determine if a likelihood that a sample includes MSI.

[0007] The processing system determines a likelihood that the sample includes MSI by selecting a set of markers from the sample reads and determining if those markers include MSI associated with cancer. A marker is a one or more reference locations identified from a sequence read or a plurality of sequence reads at a given location of a reference genome. Each marker includes a microsatellite with a microsatellite length indicating the number of times the microsatellite is repeated. For a given marker, the microsatellite length is, generally, substantially similar for control reads, and, generally, dissimilar for test reads. Differences between the markers can be quantified to determine if a given marker is significant in determining MSI. The processing system can filter the markers based on any of the characteristics of the test reads and the control reads (e.g., zygosity, read depth, etc.).

[0008] The processing system determines if a marker is significant in determining MSI by calculating, for example, a group of scores for each marker: a viability score, a significance score, an entropy score, and a divergence score. The viability score is a quantification of similarities between test reads and control reads. The significance score is a quantification of the statistical significance of the microsatellite length for a marker. The entropy score is a quantification of a difference in entropy of the marker between test reads and control reads, where entropy is the average uncertainty in microsatellite length. The divergence score is a quantification of the relative difference in the expected observation of microsatellite lengths between test reads and control reads. The processing system determines if a marker is significant based on the scores. Generally, a high viability, significance, entropy, and divergence scores result in a significant marker.

[0009] The processing system determines an instability score representing a likelihood that the sample includes MSI based on the determined marker significances. Generally, the likelihood score is a quantification of the relative number of significant to insignificant markers. Based on the instability score, the processing system can determine that a sample includes MSI and inform a method of treatment for the subject.

BRIEF DESCRIPTION OF DRAWINGS

[0010]

FIG. 1 is a flowchart of a method for preparing a nucleic acid sample for sequencing according to one embodiment.

FIG. 2 is a block diagram of a processing system for processing sequence reads according to one embodiment.

FIG. 3 is a flowchart of a method for determining variants of sequence reads according to one embodiment.

FIG. 4 is a flow chart of a method for detecting MSI, according to one example embodiment.

FIG. 5A-5B are instability plots illustrating the instability scores for metastatic prostate cancers using a method known in the art and the method of FIG. 4, according to some example embodiments.

FIG. 6 is a flow chart of a method for calculating scores for determining marker significance, according to one example embodiment.

FIGS. 7A-7D are significance plots illustrating calculated scores for determining marker significance, according to some example embodiments.

FIG. 8 is a marker plot showing data used to calculate scores for determining marker significance, according to one example embodiment.

FIG. 9A-9B are marker plots for a marker after error correction, the plots comparing a prior art method and the MSI detection method, according to some example embodiments.

FIGS. 9C-9D are characteristic plots comparing the difference in a measure of a characteristic for a marker with a high viability score after error correction, according to some example embodiments.

FIG. 10A-10B are marker plots for a marker after error correction, the plots comparing a prior art method and the MSI detection method according to some example embodiments.

FIGS. 10C-10D are characteristic plots comparing the difference in a measure of a characteristic for a marker with a low viability score after error correction, according to some example embodiments.

FIG. 11A-11B are significance plot for samples including copy number aberration, according to some example embodiments.

FIG. 11C-11D are marker plots for a marker from a sample including copy number aberrations, according to some example embodiments.

FIG. 12A-12B are instability plots illustrating the instability scores for metastatic lung cancer using a method known in the art and the method of FIG. 4, according to some example embodiments.

FIG. 13A- 13D are significance plots for various markers of a metastatic lung cancer sample using the method of FIG. 4, according to some example embodiments.

FIG. 14A-14B are instability plots illustrating the instability scores for metastatic breast cancer using a method known in the art and the method of FIG. 4, according to some example embodiments.

FIG. 15A- 15D are significance plots for various markers of a metastatic breast cancer sample using the method of FIG. 4, according to some example embodiments.

FIG. 16A- 16D are significance plots for various markers of a metastatic prostate cancer sample using the method of FIG. 4, according to some example embodiments.

[0011] The figures depict embodiments of the present invention for purposes of illustration only. One skilled in the art will readily recognize from the following discussion that alternative embodiments of the structures and methods illustrated herein may be employed without departing from the principles of the invention described herein.

DETAILED DESCRIPTION

I. DEFINITIONS

[0012] The term "individual" refers to a human individual. The term "healthy individual" refers to an individual presumed to not have a cancer or disease. The term "subject" refers to an individual who is known to have, or potentially has, a cancer or disease.

[0013] The term "sequence reads" refers to nucleotide sequences read from a sample obtained from an individual. Sequence reads can be obtained through various methods known in the art.

[0014] The term "read segment" or "read" refers to any nucleotide sequences including sequence reads obtained from an individual and/or nucleotide sequences derived from the initial sequence read from a sample obtained from an individual. For example, a read segment can refer to an aligned sequence read, a collapsed sequence read, or a stitched read. Furthermore, a read segment can refer to an individual nucleotide base, such as a single nucleotide variant.

[0015] The term "single nucleotide variant" or "SNV" refers to a substitution of one nucleotide to a different nucleotide at a position (e.g., site) of a nucleotide sequence, e.g., a sequence read from an individual. A substitution from a first nucleobase X to a second nucleobase Y may

be denoted as "X>Y." For example, a cytosine to thymine SNV may be denoted as "C>T."

[0016] The term "indel" refers to any insertion or deletion of one or more base pairs having a length and a position (which may also be referred to as an anchor position) in a sequence read. An insertion corresponds to a positive length, while a deletion corresponds to a negative length.

[0017] The term "mutation" refers to one or more SNVs or indels.

[0018] The term "true positive" refers to a mutation that indicates real biology, for example, presence of a potential cancer, disease, or germline mutation in an individual. True positives are not caused by mutations naturally occurring in healthy individuals (e.g., recurrent mutations) or other sources of artifacts such as process errors during assay preparation of nucleic acid samples.

[0019] The term "false positive" refers to a mutation incorrectly determined to be a true positive. Generally, false positives may be more likely to occur when processing sequence reads associated with greater mean noise rates or greater uncertainty in noise rates.

[0020] The term "cell-free nucleic acid," "cell-free DNA," or "cfDNA" refers to nucleic acid fragments that circulate in an individual's body (e.g., bloodstream) and originate from one or more healthy cells and/or from one or more cancer cells. cfDNA can be obtained from a blood sample.

[0021] The term "circulating tumor DNA" or "ctDNA" refers to nucleic acid fragments that originate from tumor cells or other types of cancer cells, which may be released into an individual's bloodstream as result of biological processes such as apoptosis or necrosis of dying cells or actively released by viable tumor cells. In some cases, ctDNA is DNA found in cfDNA.

[0022] The term "genomic nucleic acid," "genomic DNA," or "gDNA" refers to nucleic acid including chromosomal DNA that originates from one or more healthy cells. In some cases, white blood cells are assumed to be healthy cells.

[0023] The term "white blood cell DNA," or "wbcDNA" refers to nucleic acid including chromosomal DNA that originates from white blood cells. Generally, wbcDNA is gDNA and is assumed to be healthy DNA.

[0024] The term "tissue nucleic acid," "cancerous tissue DNA," or "tDNA" refers to nucleic acid including chromosomal DNA from tumor cells or other types of cancer cells that are obtained from cancerous tissue or a tumor. In some cases, tDNA is obtained from a biopsy of a tumor.

[0025] The term "alternative allele" or "ALT" refers to an allele having one or more mutations relative to a reference allele, e.g., corresponding to a known gene.

[0026] The term "sequencing depth" or "depth" refers to a total number of read segments from a sample obtained from an individual.

[0027] The term "alternate depth" or "AD" refers to a number of read segments in a sample that support an ALT, e.g., include mutations of the ALT.

[0028] The term "alternate frequency" or "AF" refers to the frequency of a given ALT. The AF may be determined by dividing the corresponding AD of a sample by the depth of the sample for the given ALT.

II. EXAMPLE ASSAY PROTOCOL

[0029] FIG. 1 is flowchart of a method 100 for preparing a nucleic acid sample for sequencing according to one aspect of the disclosure. The method 100 includes, but is not limited to, the following steps. For example, any step of the method 100 may comprise a quantitation substep for quality control or other laboratory assay procedures known to one skilled in the art.

[0030] In step 110, a nucleic acid sample (DNA or RNA) is extracted from a subject. In the present disclosure, DNA and RNA may be used interchangeably unless otherwise indicated. That is, the following embodiments for using error source information in variant calling and quality control may be applicable to both DNA and RNA types of nucleic acid sequences. However, the examples described herein may focus on DNA for purposes of clarity and explanation. The sample may be any subset of the human genome, including the whole genome. The sample may be extracted from a subject known to have or suspected of having cancer. The sample may include blood, plasma, serum, urine, fecal, saliva, other types of bodily fluids, or any combination thereof. In some cases, the sample can include tissue or bodily fluids extracted from tissue. In some embodiments, methods for drawing a blood sample (e.g., syringe or finger prick) may be less invasive than procedures for obtaining a tissue biopsy, which may require surgery. The extracted sample may include cfDNA and/or ctDNA. For healthy individuals, the human body may naturally clear out cfDNA and other cellular debris. If a subject has a cancer or disease, ctDNA in an extracted sample may be present at a detectable level for diagnosis.

[0031] Additionally, the extracted sample can include wbcDNA. Extracting 110 the nucleic acid sample can further include separating the cfDNA and/or ctDNA from the wbcDNA. Extracting the wbcDNA from the cfDNA and/or ctDNA can occur when the DNA is separated from the sample. In the case of a blood sample, the wbcDNA is obtained from a buff coat fraction of the blood sample. The wbcDNA can be sheared to obtain wbcDNA fragments less than 300 base pairs in length. Separating the wbcDNA from the cfDNA and/or ctDNA allows the wbcDNA to be sequenced independently from the cfDNA and/or ctDNA. Generally the sequencing process for wbcDNA is similar to the sequencing process for cfDNA and/or ctDNA.

[0032] In step 120, a sequencing library is prepared. During library preparation, unique molecular identifiers (UMI) are added to the nucleic acid molecules (e.g., DNA molecules) through adapter ligation. The UMIs are short nucleic acid sequences (e.g., 4-10 base pairs) that are added to ends of DNA fragments during adapter ligation. In some embodiments, UMIs are degenerate base pairs that serve as a unique tag that can be used to identify sequence reads originating from a specific DNA fragment. During PCR amplification following adapter ligation, the UMIs are replicated along with the attached DNA fragment, which provides a way to identify sequence reads that came from the same original fragment in downstream analysis.

[0033] In step 130, targeted DNA sequences are enriched from the library. During enrichment, hybridization probes (also referred to herein as "probes") are used to target, and pull down, nucleic acid fragments informative for the presence or absence of cancer (or disease), cancer status, or a cancer classification (e.g., cancer type or tissue of origin). For a given workflow, the probes may be designed to anneal (or hybridize) to a target (complementary) strand of DNA or RNA. The target strand may be the "positive" strand (e.g., the strand transcribed into mRNA, and subsequently translated into a protein) or the complementary "negative" strand. The probes may range in length from 10s, 100s, or 1000s of base pairs. In one embodiment, the probes are designed based on a gene panel to analyze particular mutations or target regions of the genome (e.g., of the human or another organism) that are suspected to correspond to certain cancers or other types of diseases. Moreover, the probes may cover overlapping portions of a target region. By using a targeted gene panel rather than sequencing all expressed genes of a genome, also known as "whole exome sequencing," the method 100 may be used to increase sequencing depth of the target regions, where depth refers to the count of the number of times a given target sequence within the sample has been sequenced. Increasing sequencing depth reduces required input amounts of the nucleic acid sample. After a hybridization step, the hybridized nucleic acid fragments are captured and may also be amplified using PCR.

[0034] In step 140, sequence reads are generated from the enriched DNA sequences. Sequencing data may be acquired from the enriched DNA sequences by known means in the art. For example, the method 100 may include next generation sequencing (NGS) techniques including synthesis technology (Illumina), pyrosequencing (454 Life Sciences), ion semiconductor technology (Ion Torrent sequencing), single-molecule real-time sequencing (Pacific Biosciences), sequencing by ligation (SOLiD sequencing), nanopore sequencing (Oxford Nanopore Technologies), or paired-end sequencing. In some embodiments, massively parallel sequencing is performed using sequencing-by-synthesis with reversible dye terminators.

[0035] In some embodiments, the sequence reads may be aligned to a reference genome using known methods in the art to determine alignment position information. The alignment position information may indicate a beginning position and an end position of a region in the reference genome that corresponds to a beginning nucleotide base and end nucleotide base of a given sequence read. Alignment position information may also include sequence read length, which can be determined from the beginning position and end position. A region in the

reference genome may be associated with a gene or a segment of a gene. As cfDNA and/or ctDNA and wbcDNA are sequenced independently, sequence reads for both cfDNA and/or ctDNA and wbcDNA are independently generated.

[0036] In various embodiments, a sequence read is comprised of a read pair denoted as R_1 and R_2 . For example, the first read R_1 may be sequenced from a first end of a nucleic acid fragment whereas the second read R_2 may be sequenced from the second end of the nucleic acid fragment. Therefore, nucleotide base pairs of the first read R_1 and second read R_2 may be aligned consistently (e.g., in opposite orientations) with nucleotide bases of the reference genome. Alignment position information derived from the read pair R_1 and R_2 may include a beginning position in the reference genome that corresponds to an end of a first read (e.g., R_1) and an end position in the reference genome that corresponds to an end of a second read (e.g., R_2). In other words, the beginning position and end position in the reference genome represent the likely location within the reference genome to which the nucleic acid fragment corresponds. An output file having SAM (sequence alignment map) format or BAM (binary) format may be generated and output for further analysis such as variant calling, as described below with respect to FIG. 2.

III. EXAMPLE PROCESSING SYSTEM

[0037] FIG. 2 is block diagram of a processing system 200 for processing sequence reads according to one aspect of the disclosure. The processing system 200 includes a sequence processor 205, sequence database 210, model database 215, machine learning engine 220, models 225 (for example, including one or more Bayesian hierarchical models or joint models), parameter database 230, score engine 235, variant caller 240, and instability caller 250.

[0038] FIG. 3 is flowchart of a method 300 for determining variants of sequence reads according to one aspect of the disclosure. In some embodiments, the processing system 200 performs the method 300 to perform variant calling (e.g., for SNVs and/or indels) based on input sequencing data. Further, the processing system 200 may obtain the input sequencing data from an output file associated with nucleic acid sample prepared using the method 100 described above. The method 300 includes, but is not limited to, the following steps, which are described with respect to the components of the processing system 200. In other embodiments, one or more steps of the method 300 may be replaced by a step of a different process for generating variant calls, e.g., using Variant Call Format (VCF), such as HaplotypeCaller, VarScan, Strelka, or SomaticSniper.

[0039] At step 310, the sequence processor 205 collapses aligned sequence reads of the input sequencing data. In one embodiment, collapsing sequence reads includes using UMIs, and optionally alignment position information from sequencing data of an output file (e.g., from the method 100 shown in FIG. 1) to collapse multiple sequence reads into a consensus sequence for determining the most likely sequence of a nucleic acid fragment or a portion thereof. Since

the UMIs are replicated with the ligated nucleic acid fragments through enrichment and PCR, the sequence processor 205 may determine that certain sequence reads originated from the same molecule in a nucleic acid sample. In some embodiments, sequence reads that have the same or similar alignment position information (e.g., beginning and end positions within a threshold offset) and include a common UMI are collapsed, and the sequence processor 205 generates a collapsed read (also referred to herein as a consensus read) to represent the nucleic acid fragment. The sequence processor 205 designates a consensus read as "duplex" if the corresponding pair of collapsed reads have a common UMI, which indicates that both positive and negative strands of the originating nucleic acid molecule is captured; otherwise, the collapsed read is designated "non-duplex." In some embodiments, the sequence processor 205 may perform other types of error correction on sequence reads as an alternate to, or in addition to, collapsing sequence reads.

[0040] At step 315, the sequence processor 205 stitches the collapsed reads based on the corresponding alignment position information. In some embodiments, the sequence processor 205 compares alignment position information between a first read and a second read to determine whether nucleotide base pairs of the first and second reads overlap in the reference genome. In one use case, responsive to determining that an overlap (e.g., of a given number of nucleotide bases) between the first and second reads is greater than a threshold length (e.g., threshold number of nucleotide bases), the sequence processor 205 designates the first and second reads as "stitched"; otherwise, the collapsed reads are designated "unstitched." In some embodiments, a first and second read are stitched if the overlap is greater than the threshold length and if the overlap is not a sliding overlap. For example, a sliding overlap may include a homopolymer run (e.g., a single repeating nucleotide base), a dinucleotide run (e.g., two-nucleotide base sequence), or a trinucleotide run (e.g., three-nucleotide base sequence), where the homopolymer run, dinucleotide run, or trinucleotide run has at least a threshold length of base pairs.

[0041] At step 320, the sequence processor 205 assembles reads into paths. In some embodiments, the sequence processor 205 assembles reads to generate a directed graph, for example, a de Bruijn graph, for a target region (e.g., a gene). Unidirectional edges of the directed graph represent sequences of k nucleotide bases (also referred to herein as "k-mers") in the target region, and the edges are connected by vertices (or nodes). The sequence processor 205 aligns collapsed reads to a directed graph such that any of the collapsed reads may be represented in order by a subset of the edges and corresponding vertices.

[0042] In some embodiments, the sequence processor 205 determines sets of parameters describing directed graphs and processes directed graphs. Additionally, the set of parameters may include a count of successfully aligned k-mers from collapsed reads to a k-mer represented by a node or edge in the directed graph. The sequence processor 205 stores, e.g., in the sequence database 210, directed graphs and corresponding sets of parameters, which may be retrieved to update graphs or generate new graphs. For instance, the sequence processor 205 may generate a compressed version of a directed graph (e.g., or modify an existing graph) based on the set of parameters. In one use case, in order to filter out data of a

directed graph having lower levels of importance, the sequence processor 205 removes (e.g., "trims" or "prunes") nodes or edges having a count less than a threshold value, and maintains nodes or edges having counts greater than or equal to the threshold value.

[0043] At step 325, the variant caller 240 generates candidate variants from the paths assembled by the sequence processor 205. In one embodiment, the variant caller 240 generates the candidate variants by comparing a directed graph (which may have been compressed by pruning edges or nodes in step 310) to a reference sequence of a target region of a genome. The variant caller 240 may align edges of the directed graph to the reference sequence, and records the genomic positions of mismatched edges and mismatched nucleotide bases adjacent to the edges as the locations of candidate variants. Additionally, the variant caller 240 may generate candidate variants based on the sequencing depth of a target region. In particular, the variant caller 240 may be more confident in identifying variants in target regions that have greater sequencing depth, for example, because a greater number of sequence reads help to resolve (e.g., using redundancies) mismatches or other base pair variations between sequences.

[0044] In one embodiment, the variant caller 240 generate candidate variants using a model 225 to determine expected noise rates for sequence reads from a subject. The model 225 may be a Bayesian hierarchical model, though in some embodiments, the processing system 200 uses one or more different types of models. Moreover, a Bayesian hierarchical model may be one of many possible model architectures that may be used to generate candidate variants and which are related to each other in that they all model position-specific noise information in order to improve the sensitivity/specificity of variant calling. More specifically, the machine learning engine 220 trains the model 225 using samples from healthy individuals to model the expected noise rates per position of sequence reads.

[0045] Further, multiple different models may be stored in the model database 215 or retrieved for application post-training. For example, a first model is trained to model SNV noise rates and a second model is trained to model indel noise rates. Further, the score engine 235 may use parameters of the model 225 to determine a likelihood of one or more true positives in a sequence read. The score engine 235 may determine a quality score (e.g., on a logarithmic scale) based on the likelihood. For example, the quality score is a Phred quality score $Q = -10 \cdot \log_{10} P$, where P is the likelihood of an incorrect candidate variant call (e.g., a false positive).

[0046] At step 330, the score engine 235 scores the candidate variants based on the model 225 or corresponding likelihoods of true positives or quality scores. Training and application of the model 225 is described in more detail below.

[0047] At step 335, the processing system 200 outputs the candidate variants. In some embodiments, the processing system 200 outputs some or all of the determined candidate variants along with the corresponding scores. Downstream systems, e.g., external to the processing system 200 or other components of the processing system 200, may use the

candidate variants and scores for various applications including, but not limited to, predicting presence of cancer, disease, or germline mutations.

[0048] Candidate variants are outputted for both cfDNA and/or ctDNA and wbcDNA. Herein, generally, candidate variants for wbcDNA are "normals" while candidate variants for cfDNA and/or ctDNA are "variants." Various detection methods and models can compare variants to normals to determine if the variants include signatures of cancer or any other disease. In various embodiments, normals and variants can be generated using any other process, any number of samples (e.g., a tumor biopsy or blood sample), or accessed from a database storing candidate variants.

IV. DETERMINING MICROSATELLITE INSTABILITY IN A SAMPLE

[0049] Processing system 200 generates variants and normals that can be used to detect cancer in a subject, or predict a likelihood that a subject has cancer, from a cfDNA sample. Some cancers can include microsatellite instability (MSI). Microsatellite instability is the condition of genetic hypermutability that results from impaired DNA mismatch repair (MMR). The presence of MSI represents phenotypic evidence that MMR is not functioning normally and can, in some cases, be associated with various forms of cancer. Detecting MSI, or determining a likelihood of MSI, in a subject can be useful for a variety of reasons: informing a method of treatment for the subject, determining the likelihood of curing the subject, determining the severity of the cancer, determining the progression of the cancer, etc.

[0050] Processing system 200 includes an instability caller 250 configured to determine a likelihood that generated variants include MSI. Instability caller 250 inputs variants and normals (i.e., test reads and control reads) for a sample and determines a likelihood that the sample includes MSI based on an analysis and comparison of the inputted sequences. While instability caller 250 detects MSI in variants generated by processing system 200, instability caller 250 can be used to detect MSI in any other set of DNA sequence reads.

[0051] FIG. 4 illustrates a flow diagram illustrating a MSI detection method 400 performed by instability caller 250 of processing system 200, in one example embodiment. In this example, MSI detection method 400 includes, but is not limited to, the following steps.

[0052] At step 410, sequencing data is obtained from a sample (e.g., using method 300, or accessing stored sequencing data). Generally, the data obtained from a sample includes a number of sequencing reads from cfDNA and wbcDNA obtained from a blood sample of a subject. Sequencing reads (i.e., reads) from cfDNA can include both DNA associated with cancer (i.e., ctDNA) and DNA not associated with cancer. In some samples, cfDNA can include gDNA from white blood cell fragments.

[0053] Variant caller 240 can call individual positions within the ctDNA as variants (i.e., test reads) using processing system 200. Reads from gDNA are obtained from wbcDNA or white

blood cell fragments in the sample, and are, in this case, not associated with cancer. Variant caller 240 can call individual positions within the gDNA as normals (i.e., control reads) using processing system 200. As previously described, test reads and control reads (i.e., sample reads, in aggregate) each have various characteristics such as read depth, allele frequency, bag depth, etc. Processing system 200 can analyze the differences between the test reads, the control reads, and their respective characteristics to detect MSI in the sample.

[0054] At step 420, markers associated with MSI are selected from the received datasets. As referenced herein, a marker is one or more reference locations identified from a sequence read or a plurality of sequence reads at a given location of a reference genome. Markers are associated with nucleotides that can indicate cancer when MSI is detected. For any given marker, the microsatellite lengths, or microsatellite length distribution, can be similar between test reads and control reads. In samples that do not include MSI, microsatellite lengths (or length distributions) are similar between test reads and control reads. Conversely, in samples that include MSI indicative of cancer, microsatellite lengths (or lengths distributions) are variable in test reads when compared to control reads.

[0055] Each marker can be given a marker identifier (i.e., Marker ID) describing characteristics of the marker. For example, a Marker ID can be "BAM chr2 220439700 CTCTG 5[CT] GCTGA HOM," where BAM is the read source, chr2 indicates the marker is on the second chromosome, 220439700 is a site identifier, CTCTG 5[CT] GCTGA are the set of nucleotides included in the marker, CTCTG and GCTGA are the flanking sequences of the marker, [CT] is a microsatellite in the marker (i.e., a subset of nucleotides that repeat), 5 is the microsatellite length (i.e., the number of times the microsatellite repeats) in the marker (e.g., 5 repeats of CT), and HOM is an indication of the zygosity of the marker (e.g., homozygous "HOM" or heterozygous "HET"). For each marker, any sample read that includes the marker is associated with that marker. Thus, each marker in a sample can have a number of test reads and control reads including that marker associated with it (i.e., marker reads).

[0056] At step 430, sample reads are filtered such that the specificity of the MSI detection method 400 increases. According to the invention, MSI detection method 400 removes heterozygous reads from sample reads such that determining marker significance and calculating instability scores uses only homozygous reads. In another example, detection method 400 removes marker reads if the marker reads (test, control, or both) do not have a sufficient read depth. In various other configurations the MSI detection algorithm filters the reads based on any of bag size, bag depth, marker location, microsatellite nucleotides, or any other characteristic of a read that can be filtered.

[0057] At step 440, MSI detection method 400 determines a marker significance for each marker. Marker significance represents the significance and viability for the marker in detecting MSI. Here, the viability of a marker describes a level of similarity between characteristics of test reads and control reads for the marker. The significance of a marker represents the statistical significance of test reads with dissimilar microsatellite lengths (e.g., tests reads include 5[CT], 6[CT], 7[CT], etc.) relative to the microsatellite length in the control reads (e.g., control reads

include predominantly 5[CT]). Determining 440 marker significance can include calculating any number of marker scores (e.g., significance score, divergence score, entropy score, viability score, etc.) based on the sample reads as described in the Section titled "Determining Marker Significance." Each marker is determined to be significant or insignificant, with significant markers indicating that MSI is likely in that marker and insignificant markers indicating the MSI is unlikely in that marker.

[0058] At step 450, detection method 400 determines an instability score for the sample representing the likelihood that the sample contains MSI. In one example, the instability score is a ratio of significant to insignificant markers for the sample. In another example, a weighting function using determined marker significances and/or marker scores can be used to determine an instability score. If the instability score is above a threshold level instability the caller 250 calls the sample as including MSI.

[0059] The MSI detection method (400) of the invention detects a likelihood of cancer in an individual. The MSI detection method (400) may also detect the presence of cancer, a particular type of cancer, or a degree of cancer based on the instability score. In some cases, the MSI detection method informs a method of treatment based on the instability score.

IV. A EXAMPLE OF MSI DETECTION IN A SAMPLE

[0060] FIGS. 5A-5B are example instability plots comparing MSI detection methods for metastatic prostate cancer samples, according to one example embodiment. In instability plots 510 and 520, the y-axis indicates a sample number, with each sample number being a sample from a different subject. The x-axis is the instability score representing a likelihood that the sample includes MSI. The instability score for Study DNA samples are shown with darker bars and the instability score for Sample DNA samples are shown with lighter bars. Study DNA samples are obtained from a prior art study that includes biopsies of tumors. Here, Study DNA includes both tDNA and cfDNA sequence reads. In Study DNA, tDNA and ctDNA (from the cfDNA) test reads are compared against gDNA control reads to determine the instability score for a given sample. Sample DNA is, generally, cfDNA sequence reads and can be obtained from a blood sample, extracted from a biopsy, or accessed from a sequence datastore (e.g., sequence database 210). In Sample DNA, ctDNA (from the cfDNA) tests reads are compared against gDNA (e.g., wbcDNA) test reads to determine the instability score for a sample.

[0061] FIG. 5A is an instability plot 510 showing the determined instability score of Study DNA samples and Sample DNA samples using a prior art method, according to one example embodiment. The prior art method provides more accurate detection of MSI for Study DNA than Sample DNA. Increased accuracy in MSI detection for Study DNA can be due to several contributing factors: a higher concentration of reads indicating MSI in tDNA compared to cfDNA; assumptions and errors included in the prior art method that generate MSI detection biases in ctDNA samples; and, the read depth for the Study DNA may be cause biases in MSI detection.

[0062] FIG. 5B is an instability plot 520 showing the determined instability score of Study DNA samples and Sample DNA samples using MSI detection method 400. Relative to prior art methods, MSI detection method 400 removes assumptions and errors that generate MSI detection biases, is configured for modern read depths, and is configured for detecting MSI in ctDNA samples. As a result, MSI detection method 400 determines instability scores largely similar between the Study DNA and Sample DNA. MSI detection method 400 also reduces the noise floor of the instability score for all samples.

[0063] In some cases, MSI detection using MSI detection method 400 in tDNA can be more accurate than in cfDNA. This can be caused by a higher concentration of reads indicating MSI in tDNA compared to cfDNA. For example, sample 522 of FIG. 5B indicates a high MSI likelihood in Study DNA (i.e., tDNA and cfDNA) but not Sample DNA (i.e., cfDNA). In this particular sample, there is not sufficient ctDNA in the Sample DNA to accurately determine the presence of MSI, but there is sufficient tDNA and ctDNA in the Study DNA to accurately determine the presence of MSI.

[0064] Herein, detection method 400 compares data from ctDNA test reads to gDNA control reads to detect MSI. However, various aspects of method 400 can be applied to detect MSI in any other type or set of sequence reads as long as the sequence reads include a set reads in which presence of MSI is unknown, and a set of reads in which MSI is known not to be present.

V. DETERMINING MARKER SIGNIFICANCE

[0065] FIG. 6 illustrates a flow diagram illustrating a marker significance method 600 (i.e., significance method) to determine marker significance (e.g., step 440 of FIG. 4) performed in accordance to the detection method 400, in one example embodiment. In the illustrated example, method 600 includes, but is not limited to, the following steps, and the steps can be performed in any order, not performed, or performed multiple times.

[0066] Significance method 600 involves, in part, determining 440 marker significances. This includes calculating one or more of a variety of scores. Method 600 can calculate, for each marker, one or more of a viability score 610, a significance score 620, an entropy score 630, and a divergence score 640. MSI detection method 400 determines 440 a marker significance for each marker based on whichever scores are determined. The calculated scores provide quantitative methods for measuring the significance and viability of observed microsatellite length variations when determining marker significance. MSI detection method 400 determines 450 an instability score using the determined 440 marker significances.

[0067] FIGS. 7A-7D are significance plots giving a visual example for determining marker significance from the calculated scores of method 400 for a set of markers (e.g., data points). In these figures, each marker within a sample is represented by a different data point in the plot. The data represented by each data point in the plot (e.g., the entropy score, the

significance score, the divergence score, and the viability score) is used to determine marker significances for a sample. The determined marker significances, in aggregate, can be used to determine an instability score.

[0068] In FIGS. 7A-7D, the x-axis is the entropy score, the y-axis is the significance score, the shape of the data points represent the zygosity of the marker, specifically triangle data points are heterozygous markers and circular data points are homozygous markers. The relative size of the data points represent the divergence score (i.e., a small triangle represents a low divergence score and a large triangle represents a high divergence score, etc.). Further, only markers with a viability score above a threshold viability are illustrated on the significance plot (e.g., with a read depth above 20 reads). Calculation of the viability score, the significance score, the entropy score, and the divergence score are described in Sections V.A-V.D titled "Viability Score," "Significance Score," "Entropy Score," and "Divergence Score," respectively.

[0069] Significant markers, in general, have greater magnitude, positive-valued entropy, divergence, significance, and viability scores relative to insignificant markers. Visually, significant markers are illustrated as large data points near the top right of a significance plot. However, significant markers can be in other locations of the plot in various embodiments of method 600. Significance plots including a substantial portion of significant markers relative to insignificant markers are indicative of MSI in the sample. Visually, a sample including MSI includes a large portion of large data-points near the top-right of a significance plot. A sample not including MSI includes small data-points localized about the origin of the significance plot.

[0070] FIG. 7A-B are significance plots illustrating the scores used to determine marker significance for a pair of Study DNA samples. That is, test reads and control reads used to calculate the scores and determine marker significance in this sample include both gDNA and cfDNA. FIG. 7A is significance plot 710 for a sample showing that the calculated entropy score, significance score, and divergence score are low values for a large portion of the markers, according to one example embodiment. Many of the markers are determined 440 to be insignificant markers based on the scores. Accordingly, significance plot 710 indicates the sample does not include MSI and that the instability score is low. Conversely, FIG. 7B is a significance plot 720 for a different sample where the entropy score, significance score, and divergence score are high for a large portion of the markers, according to one example embodiment. Many of the markers are determined to be significant based on the scores. Consequently, significance plot 720 indicates that the sample includes MSI and the instability score is high.

[0071] FIG. 7C-7D are significance plots used to determine marker significance in a cell-free DNA sample. FIG. 7C is a significance plot 730 showing a large number of insignificant markers indicating the sample does not include MSI, according to one example embodiment. FIG. 7D is a significance plot 740 showing a large number of significant markers indicating the sample includes MSI, according to one example embodiment.

[0072] As discussed above, each data point in a significance plot (e.g., in FIGs. 7A-7D) is a

representation of scores calculated based on test reads and control reads associated with a marker in a sample. The underlying data used to calculate these scores for a single data point / marker in a significance plot can be illustrated individually in a marker plot.

[0073] For example, FIG. 8 illustrates a marker plot 810 illustrating the distribution of the microsatellite lengths (i.e., number of repeats for a nucleotide set) for a marker in circulation DNA, according to one embodiment. The x-axis is the observed microsatellite length of a read, the y-axis is the (empirically determined) distribution of microsatellite lengths based on the reads obtained for the sample, the red bars are microsatellite lengths observed for test reads (e.g., ctDNA), and the black bars are microsatellite lengths observed for control reads (i.e., gDNA).

[0074] Marker plot 810 includes the marker identifier. In marker plot 810, the marker identifier indicates that the marker reads originate from a BAM file, the nucleotides are on chromosome two, has location identifier 220439700, and includes the set of nucleotides CTCTG 5[CT] GCTGA. For this marker, the microsatellite is the CT nucleotides with an expected microsatellite length of 5 (e.g., 5[CT]) in a sample without MSI instability. In this example, the microsatellite length is 5 in nearly all of the control reads. However, there is variation in the microsatellite length in the test reads with approximately 80 % of test reads having length 5, approximately 18% of test reads length having 6 repeats, and <2% of test reads having length 7. The illustrated variation of microsatellite length in marker plot 810 between test reads and control reads can, in some cases, be indicative of MSI instability in the sample.

[0075] The marker illustrated in marker plot 810 has a calculated entropy score of 0.689, divergence score of 0.312, significance score of 0.000. The calculated viability score is above a threshold viability score (i.e., VS_{TH}). Based on the scores, the marker in marker plot 810 determined to be significant and may indicate MSI instability.

V.A VIABILITY SCORE

[0076] Returning to the method of FIG. 6, at step 610, significance method 600 calculates a viability score representing a level of similarity between characteristics of test reads and control reads for each marker. Significance method 600 determines a high viability score for a marker if characteristics of the test reads and control reads are similar and a low viability score for a marker if characteristics of the test reads and control reads are dissimilar.

[0077] As described above, characteristics of test reads and control reads can be dissimilar for any number of reasons. In one example, MSI detection method 400 can apply an error correction model to sample reads used for determining marker significance and instability score. The error correction model can determine, and sometimes correct, sample reads that include measurement errors.

[0078] In one example, correcting sample reads that include measurement errors can include

removing reads from MSI detection method 400, but can also include other correction methods. In various configurations, the error correction model can include correction for one or more of unique molecular index correction, duplex correction, stitching, or positional error correction, and other error correction techniques. The error correction model can be more efficient for correcting some types of sample reads (and any systematic process errors used to produce those specific types of reads) over others. Here, for example, the error correction model is more efficient in correcting errors in test reads rather than control reads. However, in various other configurations, the error correction model can be more efficient in correcting any subset of system reads rather than another subset of system reads (e.g., reads for a certain site, reads for a certain marker, etc.). Correcting errors using the error correction model can change the characteristics of sample reads such that the test reads characteristics change relative to the control reads. The changed characteristics of the test reads affect the viability score of the marker. In similar examples, characteristics of control reads can change relative to test reads, control reads can change similarly to test reads, etc. Examples of sample processing characteristics that can change due to error correction can include any of bag size, length distribution, duplex rate, or sequence depth, etc.

[0079] Significance method 600 measures characteristics of test reads and control reads after applying the error correction model and calculates a viability score. In various other examples, significance method 600 can determine a viability score between any two sets of sequence reads for a given marker. Here, the viability score is a quantification of how similar the characteristics of the test reads and control reads are after error correction. For example, using the example that the error correction is more efficient at correcting test reads rather than control reads, the error correction model detects measurement errors in 30% of test reads 10% of control reads for a given marker. In this example, the error correction model corrects the errors by removing the reads including measurement errors, and, as such, the read depth for the test reads is much lower than the read depth for the control reads (assuming a similar un-corrected read depth pre-correction). Thus, significance method 600 determines a low viability score for the marker based on the discrepancy in read depths between test reads and control reads. In a counter-example, significance method 600 determines a high viability score for markers with highly similar characteristics (e.g., similar bag size).

[0080] The preceding examples of calculating a viability score are given for ease of understanding. However, the viability score can be calculated based on any number of characteristics and can quantify differences between characteristics in any number of ways (e.g., weighting, ratio analysis, etc.). For example, in an embodiment, the viability score can only be high if the number of test reads and control reads is the same. Alternatively, if there is a difference between the number of test reads and the number of control reads for a marker, the viability score for that marker will be low.

[0081] The calculated viability score can be used to determine 440 marker significance for each marker. In one example, when the viability score for a marker is below a threshold viability score, the marker is not used to calculate the instability score for the sample. That is, the marker is neither significant nor insignificant and removed from instability score

calculations. Alternatively, the marker can be determined to be insignificant if the viability score is below a threshold.

[0082] Similarly, the calculated viability score can be used to determine 450 the instability score of the sample. For example, markers with very highly similar characteristics can have a viability score greater than markers with slightly similar characteristics. In this case, MSI detection method 400 may weight marker significances higher for markers with a higher viability score than markers with lower viability scores when determining the instability score for the sample.

[0083] FIG. 9A-9D illustrate the effects of applying an error correction model on sample reads on a marker of a circulation DNA sample resulting in a high viability score.

[0084] FIG. 9A-9B are marker plots for a marker after error correction, the plots comparing a prior art method and the MSI detection method 400 for a sample including circulation DNA. In FIG. 9A, marker plot 910 illustrates the distribution of microsatellite lengths using the prior art method (without error correction, or minimal error correction), according to one example embodiment. In FIG. 9B, marker plot 920 illustrates the distribution of microsatellite lengths using MSI detection method 400 after applying an error correction model, according to one example embodiment. Here, both marker plot 910 and marker plot 920 are largely similar indicating that the error correction model did not affect the distribution of microsatellite length for this particular marker in the sample.

[0085] FIG. 9C-9D are characteristic plots illustrating a measure of similarity for a characteristic of sample reads for the marker of FIG. 9B, according to one example embodiment. The x-axis is a function of the number of reads in each bag (i.e., a particular UMI/position combination used during error correction). The y-axis is the distribution of the x-axis function. The red data points indicate the distribution of the function for test reads and the black points indicate the distribution of the function for control reads.

[0086] FIG. 9C is a characteristic plot 930 illustrating the similarity between the test reads and control reads for a first characteristic (i.e., bag size sum) of the sample reads, according to one example embodiment. The function of the x-axis in characteristic plot is the bag size sum. The bag size sum is the sum of the forward and reverse reads in the bag for the marker. A data point on characteristic plot 930 shows that for a given bag having a number of forward and reverse reads (x), a fraction (y) of bags have the same sum of forward and reverse reads in the bag. Here, the bag size sum is largely similar for both the test reads and the control reads. Thus, the MSI detection algorithm calculates that the viability score is high based on this characteristic of the sample reads.

[0087] FIG. 9D is a characteristic plot 940 illustrating the similarity between the test reads and control reads for a second characteristic (i.e., bag size min) of the reads, according to one example embodiment. The function of the x-axis in characteristic plot 940 is the bag size min. The bag size min is the minimum count of the forward and reverse reads in the bag for the

marker. In characteristic plot 940, every bag of size 0 indicates that the bag included a single strand of DNA (i.e., was not duplex). A data point on characteristic plot 940 shows that for a given bag having a minimum count of forward and reverse reads (x), a certain fraction (y) of the bags have that minimum number of forward and reverse reads in the bag. In characteristic plot 940, bag size min distribution is largely similar for both the test reads and control reads. Thus, MSI detection method 400 calculates that the viability score is high based on this characteristic. FIGS. 9C-9D suggest that the error correction model is similarly efficient for cell-free variant DNA and white blood cell DNA for this marker.

[0088] As some of the bags were not duplex, the data points do not show a full distribution across the y-axis. The lack of full distribution in characteristic plot 940 indicates that approximately 50% of the test reads were not duplex, and that approximately 50% of the control reads were not duplex.

[0089] FIG. 10A-10D illustrate the effects of applying an error correction model on sample reads of a marker for a circulation DNA sample resulting in a low viability score.

[0090] FIG. 10A-10B are marker plots for a marker after error correction, the plots comparing a prior art method and the MSI detection method 400, respectively. FIG. 10A is a marker plot 1010 illustrating the variation in microsatellite length for a marker using a prior art method (with minimal, or no, error correction), according to one example embodiment. FIG. 10B is a marker plot 1020 illustrating the variation in microsatellite length for the same marker after applying an error correction model using MSI detection method 400, according to one example embodiment. Here, both marker plot 1010 and 1020 are largely similar indicating that the error correction model did not affect the distribution of microsatellite repeat lengths in the sample.

[0091] FIG. 10C-10D are characteristic plots illustrating a measure of similarity for a characteristic of test reads and control reads for the marker of FIG. 10B, according to one example embodiment. FIGs. 10C and 10D are similar to FIGs. 9C-9D. That is, FIG. 10C is a characteristic plot 1030 illustrating a measure of similarity for the bag size sum of the marker between test reads and control reads after error correction, according to one example embodiment. FIG. 10D is a characteristic plot 1040 illustrating a measure of similarity for the bag size min of the marker between test reads and control reads after error correction, according to one example embodiment. In the examples of FIG. 10C-10D the observed characteristics (i.e., bag size sum and bag size min) are largely dissimilar for test reads and control reads. The differential between the distributions (i.e., a greater distribution of test reads relative to control reads) indicates that the error correction model was more efficient for the test reads rather than the control reads. Thus, MSI detection method 400 calculates that the viability score is low based on these characteristics. In some configurations, if the calculated viability score is below a threshold viability score, the markers are not included in determining marker significance or determining an instability score.

[0092] As some of the bags were not duplex, the data points do not show a full distribution across the y-axis. The lack of full distribution in characteristic plot 940 indicates that

approximately 60% of the test reads were not duplex, and that approximately 40% of the control reads were not duplex. In some configurations, this difference can generate a low viability score for the marker.

V.B SIGNIFICANCE SCORE

[0093] Returning to FIG. 6, at step 620, method 600 calculates a significance score for each marker representing the statistical significance of test reads with a variation in a microsatellite length of a microsatellite relative to microsatellite length of the same microsatellite in the control reads. In particular, the significance score quantifies the statistical significance of the variation in the microsatellite length distribution of test reads relative to control reads.

[0094] In one example embodiment, the significance score for a marker is the p-value of a Chi-Squared test comparing test reads to control reads. In calculating the Chi-squared test, the observed microsatellite lengths for the test reads and the expected value is the average microsatellite length of the control reads. Calculating the Chi-squared test produces a Chi-squared value. The p-value of the Chi-squared test is calculated with the Chi-squared value and 2 degrees of freedom. The calculated p-value is the significance score. In other configurations, the significance score can be calculated using other methods of quantifying a statistical significance for a marker.

[0095] A significance test is applied to the calculated significance scores to determine if a marker is significant. In one example embodiment, the significance test compares the significance score to a significance threshold α (i.e., $\alpha = .01$, $\alpha = .05$, $\alpha = 0.10$, etc.) to determine if the marker is significant. In the example where the significance score is a p-value of the chi-squared test, markers are significant if the p-values are below the significance threshold α . In another example embodiment, the significance test applies a methodology to reduce the rate of false positives in marker significance. For example, the significance test can apply the Benjamani-Hochberg correction procedure using a false discovery rate β (e.g., 5%). In this example, markers that pass the Benjamani-Hochberg correction procedure are significant markers. In various other example embodiments, the MSI detection method can use any number or types of significance tests to determine marker significance.

V.C ENTROPY SCORE

[0096] At step 630, significance method 600 calculates an entropy score for each marker representing the entropy of each marker. Here, the entropy is the entropy calculated in information theory. That is, the entropy is the average amount of information produced by a stochastic set of data. In the context of detection method 400, the entropy score is a measure of a difference in entropy of the marker between the test reads and the control reads.

[0097] To calculate the entropy score for a marker, the significance method 600 calculates an entropy metric for the test reads and control reads separately. Entropy for each marker is associated with the negative logarithm of the probability mass function for the set of nucleotides in the marker. Calculating the entropy metric for the test reads and control reads for a marker includes determining an entropy value for each read. The entropy value for a test read (or control read) is the probability of observing a microsatellite length in the test read (or control read) times the logarithm of the probability of observing the microsatellite length of the test read (or control read). The entropy metric for the test reads and control reads in the marker is the summation of the entropy values for the test reads and control reads, respectively.

[0098] In a sample including MSI, there is a variation across reads in microsatellite length which generates a high entropy metric. In a sample without MSI, there is much less variation in microsatellite lengths reads which generates a low entropy metric. Thus, for a set of test or control reads for a marker, a high entropy metric can be indicative of MSI.

[0099] Significance method 600 calculates the entropy score for a marker by comparing the entropy metric of the test reads to the entropy metric of control reads. Generally, the entropy score is the entropy metric of the test reads less the entropy metric of the control reads. Significance method 600 compares the entropy values between test reads and control reads because some control reads can have microsatellite length variation while not being indicative of MSI associated with cancer. When the entropy metric for the test reads is significantly greater than the entropy metric of the control reads the difference indicates that the microsatellite length variation can be indicative of MSI associated with cancer. Thus, the entropy score is high when a marker can be indicative of MSI, and low when the marker is not.

[0100] The MSI detection method 400 evaluates the entropy score for each marker to determine marker significance. In one example embodiment, a marker is significant if the entropy scores indicates that the test read is more disordered than the control read. In another example embodiment, the entropy score is compared to a threshold entropy score for each marker, and if the entropy score is greater than the threshold entropy score the marker is a significant marker.

V.D DIVERGENCE SCORE

[0101] Returning to FIG. 6, at step 640, significance method 600 calculates a divergence score for each marker representing a measure of the relative entropy between test reads and control reads for the marker. The divergence score measures how the probability distribution of the microsatellite lengths for the test reads diverge from the probability distribution of microsatellite length for the control reads.

[0102] In one example embodiment, the divergence score is the Jensen-Shannon divergence of test reads and control reads for each marker. In this case, to calculate the divergence score,

significance method 600 determines a probability for measuring each observed microsatellite length for test reads and control reads, respectively. For every observed microsatellite length, significance method 600 calculates a first length probability value and a second length probability value. The first length probability value compares the probability of observing the microsatellite length in test reads to a logarithmic ratio of the probability for observing the microsatellite lengths in test reads to the probability of observing the microsatellite lengths in an average of test reads and control reads. The second length probability value compares the probability of observing the microsatellite length in control reads to a logarithmic ratio of the probability for observing the microsatellite lengths in control reads to the probability of observing the microsatellite lengths in an average of test reads and control reads. The divergence score is the sum of the first and second length values for all observed microsatellite lengths. Alternatively stated, the divergence score is the expectation of observing a microsatellite length given the distributions of the test reads and control reads. In various other embodiments, the divergence score can be any scoring methodology that compares the probability distributions of test reads and control reads.

[0103] In the context of significance method 600, the divergence score measures relative differences between the probability distributions for observing a set of microsatellite lengths. Thus, in a sample that includes variations in microsatellite lengths in control reads dissimilar to variations in microsatellite lengths in test reads (or vice-versa), the divergence score is high. In sample that does not include variations in microsatellite lengths between test reads and control reads, or includes similar variations in microsatellite lengths between test reads and control reads, the divergence score is low. Generally, MSI causes larger variations in microsatellite lengths in test reads relative to control reads and, hence, the divergence score for a sample including MSI is high.

[0104] The significance method 600 evaluates the divergence score for each marker to determine marker significance. In one example embodiment, the divergence score is compared to a threshold divergence score for each marker. The significance method 600 defines a marker as significant if the divergence score is greater than the threshold divergence score.

VI. FILTERING

[0105] As previously described, the MSI detection method can filter the test reads based on any number of criteria.

VI.A ZYGOSITY FILTERING

[0106] In heterozygous reads, copy number aberrations can generate biases in calculating scores used for determining marker significance and instability scores. That is, a copy number

aberration in a read can be viewed by detection method 400 as a variation in the microsatellite length. Variations in microsatellite length not caused by microsatellite instability can increase the number of false positives of detection method 400.

[0107] To illustrate this, FIGS. 11A-11B are significance plots of samples not including microsatellite instability but including markers with high significance scores, high divergence scores, and low entropy scores. Significance plot 1110 illustrates a sample using both gDNA and cfDNA and significance plot 1120 illustrates a sample using cfDNA. In these examples, some of the markers may be significant markers even when not including MSI signatures. Notably, many heterozygous markers (i.e., triangle shapes) are markers that have high significance and divergence scores that may be determined as significant markers.

[0108] FIGS. 11C-11D are marker plots for a single heterozygous marker with a high significance and divergence score. In this example, an error correction model has not been applied to the markers. FIG. 11C is a marker plot 1130 showing data for a heterozygous marker from significance plot 1110, according to one example embodiment, according to one example embodiment. FIG. 11D is a marker plot 1140 showing data for a heterozygous marker from significance plot 1120. In the heterozygous markers, the probability distribution for microsatellite length is greater in the control reads than the test reads for both cfDNA and the combination of gDNA and cfDNA. The increased microsatellite length distribution in control reads over test reads is indicative of copy number aberration rather than MSI. In some cases, these markers may be incorrectly determined to be significant markers and may influence correct determination of the instability score for the sample. Accordingly, in some example embodiments, MSI detection method 400 can filter heterozygous reads before determining marker significance to increase specificity of MSI detection.

VII. EXAMPLES

VII.A LUNG

[0109] FIG. 12A is an instability plot 1210 of metastatic lung samples using a prior art method, according to one example embodiment. FIG. 12B is an instability plot 1220 metastatic lung samples using detection method 400, according to one example embodiment. Here, detection method 400 improves the sensitivity in MSI detection over the prior art method.

[0110] FIGS. 13A-13D are significance plots 1310-1340 of metastatic lung samples not including microsatellite instability. The samples are all from sample DNA in FIG. 13B. Significance plots 1310 and 1320 illustrate samples using cfDNA and gDNA and significance plot 1330 and 1340 illustrate a sample using cfDNA. The illustrated examples are for samples shown to have a high MSI score using a method known in the art and a low MSI score using method 400.

VII.B BREAST

[0111] FIG. 14A is an instability plot 1410 of metastatic breast samples using a prior art method, according to one example embodiment. FIG. 14B is an instability plot 1420 metastatic breast samples using detection method 400, according to one example embodiment. Here, detection method 400 improves the sensitivity in MSI detection over the prior art method.

[0112] FIGS. 15A-15D are significance plots of metastatic breast samples not including microsatellite instability. The samples are all from the sample DNA in FIG. 14B. Significance plots 1510 and 1520 illustrate samples using gDNA and cfDNA and significance plot 1530 and 1540 illustrate a sample using cfDNA. The illustrated examples are for samples shown to have a high MSI score using a method known in the art and a low MSI score using method 400.

VII.C PROSTATE

[0113] FIG. 5A is an instability plot 510 of metastatic prostate samples using a prior art method, according to one example embodiment. FIG. 5B is an instability plot 520 metastatic prostate samples using detection method 400, according to one example embodiment. Here, detection method 400 improves the sensitivity in MSI detection over the prior art method.

[0114] FIGS. 16A-16D are significance plots of metastatic prostate samples not including microsatellite instability. The samples are all from the sample DNA in FIG. 5B. Significance plots 1610 and 1620 illustrate samples using gDNA and cfDNA and significance plot 1630 and 1640 illustrate a sample using cfDNA. The illustrated examples are for samples shown to have a high MSI score using a method known in the art and a low MSI score using method 400.

VII. ADDITIONAL CONSIDERATIONS

[0115] The foregoing description of the embodiments of the invention has been presented for the purpose of illustration; it is not intended to be exhaustive or to limit the invention to the precise forms disclosed. Persons skilled in the relevant art can appreciate that many modifications and variations are possible in light of the above disclosure.

[0116] Some portions of this description describe the embodiments of the invention in terms of algorithms and symbolic representations of operations on information. These algorithmic descriptions and representations are commonly used by those skilled in the data processing arts to convey the substance of their work effectively to others skilled in the art. These operations, while described functionally, computationally, or logically, are understood to be implemented by computer programs or equivalent electrical circuits, microcode, or the like. Furthermore, it has also proven convenient at times, to refer to these arrangements of

operations as modules, without loss of generality. The described operations and their associated modules may be embodied in software, firmware, hardware, or any combinations thereof.

[0117] Any of the steps, operations, or processes described herein may be performed or implemented with one or more hardware or software modules, alone or in combination with other devices. In one embodiment, a software module is implemented with a computer program product including a computer-readable non-transitory medium containing computer program code, which can be executed by a computer processor for performing any or all of the steps, operations, or processes described.

[0118] Aspects of the disclosure may also relate to a product that is produced by a computing process described herein. Such a product may include information resulting from a computing process, where the information is stored on a non-transitory, tangible computer readable storage medium and may include any embodiment of a computer program product or other data combination described herein.

[0119] Finally, the language used in the specification has been principally selected for readability and instructional purposes, and it may not have been selected to delineate or circumscribe the inventive subject matter. It is therefore intended that the scope of the invention be limited not by this detailed description, but rather by any claims that issue on an application based hereon. Accordingly, the disclosure of the embodiments of the invention is intended to be illustrative, but not limiting, of the scope of the invention, which is set forth in the following claims.

REFERENCES CITED IN THE DESCRIPTION

Cited references

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US20140235456A1 [0003]

Patentkrav

1. En computerimplementeret fremgangsmåde (400) til påvisning af en sandsynlighed for kræft hos et individ baseret på mikrosatellit instabilitet (MSI), fremgangsmåden omfatter:

- 5 adgang (410) til en flerhed af test aflæsninger og en flerhed af kontrollæsninger associeret med en prøve;
- udvælgelse (420) af en flerhed af markører fra test aflæsningerne og kontrol aflæsningerne, hver markør identificerer et sæt nukleotider fra aflæsningerne,
- 10 hvor markørerne er kendt som værende associeret med mikrosatellit instabilitet i kræft;
- filtrering (430) af flerheden af markører, således at specificiteten af at bestemme en instabilitetsscore øges; filtreringen omfattende fjernelse af heterozygotiske aflæsninger fra prøve aflæsninger, således at bestemmelse af
- 15 markørsignifikans og beregning af instabilitetsscorer kun benytter homozygote aflæsninger,
- for hver markør beregnes (440) en markørsignifikans, der angiver markørens signifikans og levedygtighed ved påvisning af MSI,
- hvor levedygtigheden repræsenterer et niveau af lighed mellem karakteristika
- 20 ved test aflæsninger og kontrol aflæsninger af markøren, og
- hvor signifikansen repræsenterer den statistiske signifikans af en længdevariation af en gentagen undergruppe af nukleotider i sættet af nukleotider i test aflæsninger af markøren i forhold til længdevariationen for den samme gentagne undergruppe af nukleotider i kontrol aflæsningerne af markøren;
- 25 hvori beregning af markørsignifikansen omfatter beregning af markørscorer baseret på prøve aflæsningerne, hvor markørscorerne inkluderer en signifikansscore og en levedygtighedsscore,
- hvori beregning af signifikansscoren omfatter kvantificering af den statistiske signifikans af variationen i mikrosatellit længdefordelingen af test aflæsninger
- 30 i forhold til kontrol aflæsninger,
- hvori beregning af levedygtighedsscoren omfatter bestemmelse af en høj levedygtighedsscore over en tærskellevedygtighedsscore, hvis antallet af test aflæsninger og kontrollæsninger er det samme, og en lav levedygtighedsscore under tærskellevedygtighedsscoren for den pågældende markør, hvis der er
- 35 forskel mellem antallet af test aflæsninger og antallet af kontrollæsninger for en markør,
- bestemmelse af en instabilitetsscore (450) for prøven baseret på den beregnede markørsignifikansscore, hvor instabilitetsscoren er et forhold mellem

signifikante og insignifikante markører, der repræsenterer en sandsynlighed for, at prøven indeholder MSI, og påviser en sandsynlighed for kræft baseret på sandsynligheden for, at prøven indeholder en MSI;

hvor i bestemmelse af en instabilitetsscore omfatter

5 - når markørens levedygtighedsscore ligger under tærskellevedygtighedsscoren, ikke at anvende markøren til at beregne instabilitetsscoren for prøven, og når levedygtighedsscoren for markøren ligger over tærskellevedygtighedsscoren, anvendelse af markøren til at beregne instabilitetsscoren for prøven, og

10 - ved at sammenligne signifikansscoren med en signifikanstærskel, der til brug i instabilitetsscoren bestemmer, om markøren er en signifikant markør eller en insignifikant markør.

15 2. Fremgangsmåden ifølge krav 1, hvor i bestemmelse af markørsignifikansen yderligere omfatter:

beregning af en entropiscore, der repræsenterer entropien for hver markør, entropiscoren et mål for en forskel i markørens entropi mellem testaflysninger og kontrolaflysninger, hvor entropi er den gennemsnitlige usikkerhed i rækken af nukleotider i sættet af nukleotider;

20 eventuelt, hvor i forskellen i markørens entropi er testaflysningens entropi minus entropien for kontrolaflysningen; og/eller

eventuelt, hvor i bestemmelse af markørsignifikansen inklusive beregning af en entropiscore yderligere omfatter:

25 evaluering af forskellen i entropi for hver markør, hvor i markører med forskellen i entropi, der indikerer at testaflysningen er mere i uorden end kontrolaflysningen, udgør signifikante markører.

30 3. Fremgangsmåden ifølge krav 1 eller 2, hvor i bestemmelse af markørsignifikansen yderligere omfatter:

beregning af en divergensscore, der repræsenterer den relative entropi for markøren, hvor divergensscoren er et mål for en relativ forskel i forventet observation af længdevariationen mellem testaflysninger og kontrolaflysninger.

35

4. Fremgangsmåden ifølge krav 3, hvor i bestemmelse af markørsignifikansen, inklusive beregningen af nævnte divergensscore, yderligere omfatter:

5 sammenligning af markørens divergensscore med en tærskeldivergensscore, markørerne med divergensscoren større end tærskeldivergensscore udgør signifikante markører; og/eller
 hvori divergensscoren er Jenson-Shannon-divergensen mellem testaflysninger og kontrolaflysninger.

5. Fremgangsmåden ifølge krav 1, hvori bestemmelse af markørsignifikansen inklusive beregning af nævnte signifikansscore yderligere omfatter:
 10 anvendelse af en signifikanstest på signifikansscoren for hver markør, hvor markørerne, der består signifikanstesten, udgør signifikante markører.

6. Fremgangsmåden ifølge krav 5, hvori signifikanstesten er Benjamini-Hochberg-korrektionen; og/eller
 15 hvori signifikanstesten er en fremgangsmåde til påvisning af falske opdagelsessatser.

7. Fremgangsmåden ifølge krav 6, hvori bestemmelse af markørsignifikansen omfatter:
 20 anvendelse af en fejlkorrigeringsmodel på et sæt målefejl i testaflysninger, hvor fejlkorrigeringsmodellen bestemmer og korrigerer et kendetegn ved testaflysninger, et kendetegn ved prøvningslysninger, inklusive enhver form for posestørrelse, længdefordeling, duplekshastighed eller sekvensdybde;
 25 eventuelt, hvori levedygtighedsscoren kvantificerer lighederne mellem kendetegnene i testaflysninger og kontrolaflysninger; og/eller
 eventuelt, hvori fejlkorrigeringsmodellen er en hvilken som helst af: unik molekylær indeksskorrektion, dupleksskorrektion, hæftning eller positionel fejlkorrektion.

30

8. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 7, hvori hver markør i flerheden af markører har mindst en tærskelaflysningsdybde for testaflysninger og kontrolaflysninger; og/eller
 35 hvori testaflysninger og kontrolaflysninger er opnået fra cellefri nukleinsyre; og/eller
 hvori testaflysninger og kontrolaflysninger er opnået fra en prøve, der tidligere var kendt for ikke at omfatte kræftceller; og/eller

hvor kontrolaflæsningerne opnås fra en sekundær prøve, der tidligere var kendt for ikke at omfatte mikrosatellit instabilitet.

- 5 9. Et system bestående af en eller flere processorer og en eller flere hukommelser, der lagrer computerinstruktioner til påvisning af en sandsynlighed for kræft hos et individ baseret på mikrosatellit instabilitet (MSI), hvor instruktionerne, når de udføres af en eller flere processorer, får processoren til at udføre trin der inkluderer:
 - 10 Adgang (410) til en flerhed af testaflæsninger og en flerhed af kontrollæsninger associeret med en prøve;
 - udvælgelse (420) af en flerhed af markører fra testaflæsningerne og kontrolaflæsningerne, hvor hver markør identificerer et sæt nukleotider fra aflæsningerne, hvor markørerne er kendt som værende associeret med mikrosatellit instabilitet i kræft;
 - 15 filtrering (430) af flerheden af markører, således at specificiteten af at bestemme en ustabilitetsscore (450) øges; filtreringen omfattende fjernelse af heterozygotiske aflæsninger fra prøveaflæsninger, således at bestemmelse af markørsignifikans og beregning af instabilitetsscorer kun bruger homozygote aflæsninger,
 - 20 for hver markør beregnes en markørsignifikans, der angiver markørens signifikans og levedygtighed ved påvisning af MSI,
 - hvor levedygtigheden repræsenterer et niveau af lighed mellem karakteristika ved testaflæsninger og kontrolaflæsninger af markøren, og
 - hvor signifikansen repræsenterer den statistiske signifikans af en længdevariation af en gentagen undergruppe af nukleotider i sættet af nukleotider i testaflæsninger af markøren, i forhold til længdevariationen for den samme gentagne undergruppe af nukleotider i kontrolaflæsningerne af markøren;
 - 25 hvori beregning af markørsignifikansen omfatter beregning af markørscore baseret på prøveaflæsningerne, hvor markørscorerne inkluderer en signifikansscore og en levedygtighedsscore,
 - 30 hvori beregning af signifikansscoren omfatter kvantificering af den statistiske signifikans af variationen i mikrosatellit længdefordelingen af testaflæsninger i forhold til kontrolaflæsninger,
 - hvor beregningen af levedygtighedsscoren omfatter bestemmelse af en høj levedygtighedsscore over en tærskellevedygtighedsscore, hvis antallet af testaflæsninger og kontrolaflæsninger er det samme, og en lav levedygtighedsscore under tærskellevedygtighedsscoren for den pågældende markør,
 - 35

- hvis der er en forskel mellem antallet af testaflæsninger og antallet af kontrolaflæsninger for en markør,
- bestemmelse (450) af en instabilitetsscore for prøven baseret på de beregnede markørsignifikansscore, instabilitetsscoren et forhold mellem signifikante og insignifikante markører, der repræsenterer en sandsynlighed for, at prøven indeholder MSI, og påviser en sandsynlighed for kræft baseret på sandsynligheden for, at prøven indeholder en MSI;
- hvor i bestemmelse af en instabilitetsscore omfatter
- når markørens levedygtighedsscore ligger under tærskellevedygtighedsscoren, ikke at anvende markøren til at beregne instabilitetsscoren for prøven, og når levedygtighedsscoren for markøren ligger over tærskellevedygtighedsscoren, anvendelse af markøren til at beregne instabilitetsscoren for prøven, og
 - ved at sammenligne signifikansscoren med en signifikanstærskel, der til brug i instabilitetsscoren bestemmer, om markøren er en signifikant markør eller en insignifikant markør.

10. System ifølge krav 9, hvor i bestemmelse af markørsignifikansen yderligere bevirker, at en eller flere processorer udfører trin, inklusive:
- beregning af en entropiscore, der repræsenterer entropien for hver markør, hvor entropiscoren er et mål for en forskel i markørens entropi mellem testaflæsningerne og kontrolaflæsningerne, hvor entropi er den gennemsnitlige usikkerhed i rækken af nukleotider i sættet af nukleotider;
 - eventuelt, hvor i forskellen i markørens entropi er testaflæsningens entropi minus entropien af kontrolaflæsningen.

11. System ifølge krav 10, hvor i bestemmelse af markørsignifikansen, inklusive beregning af nævnte entropiscore, yderligere får den ene eller flere processorer til at udføre trin, inklusive:
- evaluering af forskellen i entropi for hver markør, hvor i markører med forskellen i entropi, der indikerer testaflæsningen er mere i uorden end kontrolaflæsningen, betegnes som signifikante markører.

12. System ifølge et hvilket som helst af kravene 9 til 11, hvor i bestemmelse af markørsignifikansen yderligere bevirker, at en eller flere processorer udfører trin, inklusive:

beregning af en divergensscore, der repræsenterer den relative entropi for markøren, hvor divergensscoren er et mål for en relativ forskel i forventet observation af længdevariationen mellem testaflysninger og kontrolaflysninger.

- 5 13. System ifølge krav 12, hvori bestemmelse af markørsignifikansen inklusive beregning af nævnte divergensscore yderligere får den ene eller flere processorer til at udføre trin, inklusive:

10 sammenligning af divergensscoren for markøren med en tærskeldivergensscore, hvor markørerne med divergensscoren større end tærskeldivergensscoren betegnes som signifikante markører og/eller
hvori divergensscoren er Jenson-Shannon-divergensen mellem testaflysningerne og kontrolaflysningerne.

- 15 14. Systemet ifølge krav 9, hvori bestemmelse af markørsignifikansen, inklusive beregning af signifikansscore, yderligere får den ene eller flere processorer til at udføre trin, inklusive:

20 at anvende en signifikanstest på signifikansscoren for hver markør, hvor de markører, der består signifikansprøven, betegnes som signifikante markører; eventuelt, hvori signifikanstesten er Benjamini-Hochberg-korrektionen; og/eller
eventuelt, hvori signifikanstesten er en fremgangsmåde til påvisning af falske opdagelseshastigheder.

- 25 15. System ifølge krav 14, hvori bestemmelse af markørsignifikansen yderligere bevirker, at en eller flere processorer udfører trin, inklusive:

30 anvendelse af en fejlkorrektionsmodel på et sæt målefejl i testaflysningerne, hvor fejlkorrektionsmodellen bestemmer og korrigerer et kendetegn ved testaflysningerne, et kendetegn ved prøvningsaflysningerne, inklusive enhver form for posestørrelse, længdefordeling, duplekshastighed eller sekvensdybde;
eventuelt, hvori levedygtighedsscoren kvantificerer lighederne mellem kendetegnet i testaflysningerne og kontrolaflysningerne; og/eller
35 eventuelt, hvori fejlkorrektionsmodellen er en hvilken som helst af: unik molekylær indeksskorrektion, dupleksskorrektion, hæftning eller positionel fejlkorrektion.

16. System ifølge et hvilket som helst af kravene 9 til 15, hvori hver markør i flerheden af markører har mindst en tærskelaflæsningsdybde for testaflysninger
- 5 og kontrolaflysninger; og/eller
- hvori testaflysninger og kontrolaflysninger er opnået fra cellefri nukleinsyre; og/eller
- hvori testaflysninger og kontrolaflysninger er opnået fra en prøve, der tidligere var kendt for ikke at omfatte kræftceller; og/eller
- 10 hvori kontrolaflysninger opnås fra en sekundær prøve, der tidligere var kendt for ikke at omfatte mikrosatellit instabilitet.

DRAWINGS

Drawing




FIG. 1




FIG. 2


300

FIG. 3




FIG. 4




FIG. 5A




FIG. 5B




FIG. 6




FIG. 7A




FIG. 7B




FIG. 7D




FIG. 7C




FIG. 8




FIG. 9A

FIG. 9B




FIG. 9D




FIG. 9C




FIG. 10B




FIG. 10A




FIG. 10D




FIG. 10C




FIG. 11B




FIG. 11A




FIG. 11D




FIG. 11C




FIG. 12A








FIG. 12B






FIG. 14A







FIG. 14B




Significance Plot 1510
FIG. 15A




Significance Plot 1530
FIG. 15C




Significance Plot 1520
FIG. 15B




Significance Plot 1540
FIG. 15D




Significance Plot 1610 **FIG. 16A**



Significance Plot 1630 **FIG. 16C**



Significance Plot 1620 **FIG. 16B**



Significance Plot 1640 **FIG. 16D**